List view / Grid view
Filter the results
EU marketing authorisation has been given to Sunosi (solriamfetol) for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea.
The EMA CHMP has revealed its suggestion to grant marketing authorisation to seven medicines after its most recent meeting.
The FDA has given the XWL-008 compound Orphan Drug Designation for the treatment of narcolepsy.